Mutation Screening for Thrombophilia: Two Cases with Factor V Cambridge without Activated Protein C Resistance

• References

• 1 Leyte A, Smits PHM, van Straalen JP, van Doom LJ, Quint WGV. Automated, simultaneous detection of the factor V Leiden and prothrombin (G20210A) variants using multiplex PCR and a line probe assay. Thromb Haemost 2000; 83: 354-5.
• 2 Reitsma PH. Genetic principles underlying disorders of procoagulant and anticoagulant proteins. In: Hemostasis and Thrombosis. Basic principles and clinical practice. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. (eds). Lippincott: Williams and Wilkins; 4th edition.
• 3 Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg 306-thr) associated with resistance to activated protein C. Blood 1998; 91: 1140-4.
• 4 Franco RF, Elion J, Tavella MH, Santos SEB, Zago MA. The prevalence of factor V Arg 306-Thr (factor V Cambridge) and factor V Arg 306-Gly mutations in different human populations. Thromb Haemost 1999; 81: 312-3.
• 5 Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa MV, Bozzo M, Mannucci PM. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000; 343: 1015-8.
• 6 Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517-32.